{
    "4 25 2025": {
        "importantArticles": [
            {
                "headline": "Companies in The News Are: BMY,MRK,PEP,UNP",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "MRK",
                "title": "Company News for Apr 25, 2025",
                "url": "https://finance.yahoo.com/news/company-news-apr-25-2025-132500748.html"
            },
            {
                "headline": "Q1 2025 Merck & Co Inc Earnings Call",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Thomson Reuters StreetEvents",
                "ticker": "MRK",
                "title": "Q1 2025 Merck & Co Inc Earnings Call",
                "url": "https://finance.yahoo.com/news/q1-2025-merck-co-inc-044916451.html"
            },
            {
                "headline": "Merck stock reversed higher Thursday, though the company reported another quarter of light sales for its HPV vaccine, Gardasil.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "MRK",
                "title": "Merck Stock Reverses, Though Gardasil 'Woes' Continue In China, Japan",
                "url": "https://finance.yahoo.com/m/08e7c6e4-d3b9-3da2-9c0f-bc97fc9cf269/merck-stock-reverses-though.html"
            },
            {
                "headline": "\ud83d\udd0e After-Hours Earnings: Shares of Google-parent Alphabet and Gilead Sciences rose after earnings releases late Wednesday, while shares of Intel, T-Mobile and Skechers fell. \u2198\ufe0f IBM (IBM): The tech company warned that macroeconomic uncertainty was prompting businesses to rethink spending.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "-0.0258",
                "source": "The Wall Street Journal",
                "ticker": "MRK",
                "title": "Stocks to Watch Recap: Alphabet, Intel, P&G, Merck",
                "url": "https://finance.yahoo.com/m/b43a1dbf-f797-39e8-a512-04fe9c519fcc/stocks-to-watch-recap-.html"
            },
            {
                "headline": "Merck stock reversed higher Thursday, though the company reported another quarter of light sales for its HPV vaccine, Gardasil.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "MRK",
                "title": "Merck Stock Reverses, Though Gardasil 'Woes' Continue In China, Japan",
                "url": "https://finance.yahoo.com/m/08e7c6e4-d3b9-3da2-9c0f-bc97fc9cf269/merck-stock-reverses-though.html"
            },
            {
                "headline": "Q1 2025 Merck & Co Inc Earnings Call",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Thomson Reuters StreetEvents",
                "ticker": "MRK",
                "title": "Q1 2025 Merck & Co Inc Earnings Call",
                "url": "https://finance.yahoo.com/news/q1-2025-merck-co-inc-044916451.html"
            }
        ],
        "avgScore": -0.00645,
        "pctChange": 0.03480105998815003
    },
    "4 24 2025": {
        "importantArticles": [
            {
                "headline": "Merck (NYSE:MRK) experienced a 2.98% share price increase over the past week, during which several key developments occurred. The company reaffirmed its 2025 financial guidance, despite a slight decline in Q1 sales and ongoing patent litigation with Halozyme Therapeutics. Meanwhile, broader market movements, boosted by a tech-driven rally and anticipation of tariff news, provided a favorable backdrop. The market, seeing an overall 2.3% increase, suggested positive sentiment, possibly...",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9274",
                "source": "Simply Wall St.",
                "ticker": "MRK",
                "title": "Merck (NYSE:MRK) Faces Patent Lawsuit As Earnings Grow US$317 Million In Q1",
                "url": "https://finance.yahoo.com/news/merck-nyse-mrk-faces-patent-180744722.html"
            },
            {
                "headline": "Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street\u2019s revenue expectations in Q1 CY2025, but sales fell by 1.6% year on year to $15.53 billion. The company expects the full year\u2019s revenue to be around $64.85 billion, close to analysts\u2019 estimates. Its non-GAAP profit of $2.22 per share was 4% above analysts\u2019 consensus estimates.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7684",
                "source": "StockStory",
                "ticker": "MRK",
                "title": "Merck\u2019s (NYSE:MRK) Q1 Sales Beat Estimates",
                "url": "https://finance.yahoo.com/news/merck-nyse-mrk-q1-sales-110727855.html"
            },
            {
                "headline": "RAHWAY, N.J. (AP) \u2014 Merck & Co. (MRK) on Thursday reported first-quarter earnings of $5.08 billion. On a per-share basis, the Rahway, New Jersey-based company said it had profit of $2.01. Earnings, adjusted for one-time gains and costs, came to $2.22 per share.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7579",
                "source": "Associated Press Finance",
                "ticker": "MRK",
                "title": "Merck: Q1 Earnings Snapshot",
                "url": "https://finance.yahoo.com/news/merck-q1-earnings-snapshot-104017370.html"
            },
            {
                "headline": "Merck\u2019s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 adjusted earnings projection, partly to account for recently imposed tariffs.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.6428",
                "source": "The Wall Street Journal",
                "ticker": "MRK",
                "title": "Merck Cuts 2025 Outlook on Tariffs, Charges",
                "url": "https://finance.yahoo.com/m/bf2553e4-1163-3458-8d6a-16031da27ed8/merck-cuts-2025-outlook-on.html"
            },
            {
                "headline": "The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it\u2019ll have\u00a0for the rest of the year and beyond.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4215",
                "source": "BioPharma Dive",
                "ticker": "MRK",
                "title": "Merck takes $200M tariff hit, trimming its gross profits",
                "url": "https://finance.yahoo.com/news/merck-takes-200m-tariff-hit-114300618.html"
            },
            {
                "headline": "MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3919",
                "source": "Zacks",
                "ticker": "MRK",
                "title": "Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut",
                "url": "https://finance.yahoo.com/news/merck-q1-earnings-sales-beat-182000451.html"
            }
        ],
        "avgScore": 0.08249166666666664,
        "pctChange": 0.03907819250614537
    },
    "4 23 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 20 Best Stock To Buy According to Marjorie Taylor Greene. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks to buy according to Marjorie Taylor Greene. Marjorie Taylor Greene is one of the most active members of [\u2026]",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8016",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co., Inc. (MRK) the Best Stock To Buy According to Marjorie Taylor Greene?",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-best-170817705.html"
            },
            {
                "headline": "Global pharmaceutical company Merck (NYSE:MRK) will be reporting results tomorrow before market hours. Here\u2019s what to expect.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "StockStory",
                "ticker": "MRK",
                "title": "Merck (MRK) Reports Q1: Everything You Need To Know Ahead Of Earnings",
                "url": "https://finance.yahoo.com/news/merck-mrk-reports-q1-everything-120232660.html"
            },
            {
                "headline": "We recently compiled a list of Billionaire Prem Watsa\u2019s 10 Stock Picks With Highest Potential. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against Prem Watsa\u2019s other stock picks. Momentum and technology stocks have dominated the markets over the past decade. They have been the catalyst [\u2026]",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Merck & Co., Inc. (MRK): Among Prem Watsa\u2019s Stock Picks With Highest Potential",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-among-010136693.html"
            },
            {
                "headline": "We recently compiled a list of Billionaire Prem Watsa\u2019s 10 Stock Picks With Highest Potential. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against Prem Watsa\u2019s other stock picks. Momentum and technology stocks have dominated the markets over the past decade. They have been the catalyst [\u2026]",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Merck & Co., Inc. (MRK): Among Prem Watsa\u2019s Stock Picks With Highest Potential",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-among-010136693.html"
            },
            {
                "headline": "Global pharmaceutical company Merck (NYSE:MRK) will be reporting results tomorrow before market hours. Here\u2019s what to expect.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "StockStory",
                "ticker": "MRK",
                "title": "Merck (MRK) Reports Q1: Everything You Need To Know Ahead Of Earnings",
                "url": "https://finance.yahoo.com/news/merck-mrk-reports-q1-everything-120232660.html"
            },
            {
                "headline": "We recently published a list of 20 Best Stock To Buy According to Marjorie Taylor Greene. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks to buy according to Marjorie Taylor Greene. Marjorie Taylor Greene is one of the most active members of [\u2026]",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8016",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co., Inc. (MRK) the Best Stock To Buy According to Marjorie Taylor Greene?",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-best-170817705.html"
            }
        ],
        "avgScore": 0.2672,
        "pctChange": 0.013970008940363888
    },
    "4 22 2025": {
        "importantArticles": [
            {
                "headline": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA\u00ae (pembrolizumab), Merck's anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). The approval is based on data from the pivotal Phase 3 IND.227/KEYNOTE-483 trial, which demonstrated a statistically significant improvement",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.926",
                "source": "CNW Group",
                "ticker": "MRK",
                "title": "Health Canada Approves KEYTRUDA\u00ae Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)",
                "url": "https://finance.yahoo.com/news/health-canada-approves-keytruda-plus-110000111.html"
            },
            {
                "headline": "When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5994",
                "source": "Zacks",
                "ticker": "MRK",
                "title": "Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?",
                "url": "https://finance.yahoo.com/news/merck-q1-earnings-coming-buy-113200343.html"
            },
            {
                "headline": "When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5994",
                "source": "Zacks",
                "ticker": "MRK",
                "title": "Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?",
                "url": "https://finance.yahoo.com/news/merck-q1-earnings-coming-buy-113200343.html"
            },
            {
                "headline": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA\u00ae (pembrolizumab), Merck's anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). The approval is based on data from the pivotal Phase 3 IND.227/KEYNOTE-483 trial, which demonstrated a statistically significant improvement",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.926",
                "source": "CNW Group",
                "ticker": "MRK",
                "title": "Health Canada Approves KEYTRUDA\u00ae Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)",
                "url": "https://finance.yahoo.com/news/health-canada-approves-keytruda-plus-110000111.html"
            }
        ],
        "avgScore": 0.7627,
        "pctChange": -0.0029125408810718755
    },
    "4 17 2025": {
        "importantArticles": [
            {
                "headline": "In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023. In 2023, the healthcare industry made up 17.6% of the US economy, an increase of 17.4% from 2022. The growth of Medicare and private [\u2026]",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7184",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Merck & Co., Inc. (MRK): Among the Innovative Healthcare Stocks to Watch in 2025",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-among-135553479.html"
            },
            {
                "headline": "Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2263",
                "source": "Zacks",
                "ticker": "MRK",
                "title": "Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
                "url": "https://finance.yahoo.com/news/merck-mrk-earnings-expected-grow-140101939.html"
            },
            {
                "headline": "Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let\u2019s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "StockStory",
                "ticker": "MRK",
                "title": "Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers",
                "url": "https://finance.yahoo.com/news/pharmaceuticals-stocks-q4-review-jazz-090614474.html"
            },
            {
                "headline": "We recently published a list of 10 Dirt Cheap Stocks To Invest In Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other dirt cheap stocks to invest in now. Investor\u2019s Guide to Navigating the Volatilitc The stock market has been experiencing volatility and [\u2026]",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5859",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co., Inc. (MRK) The Dirt Cheap Stock To Invest In Now?",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-dirt-171334421.html"
            },
            {
                "headline": "Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1621",
                "source": "Zacks",
                "ticker": "MRK",
                "title": "Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock",
                "url": "https://finance.yahoo.com/news/know-beyond-why-merck-co-130014205.html"
            },
            {
                "headline": "Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let\u2019s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "StockStory",
                "ticker": "MRK",
                "title": "Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers",
                "url": "https://finance.yahoo.com/news/pharmaceuticals-stocks-q4-review-jazz-090614474.html"
            }
        ],
        "avgScore": 0.03934000000000002,
        "pctChange": -0.0019230964856270032
    },
    "4 16 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big [\u2026]",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9274",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co., Inc. (MRK) the Best Pharma Stock to Buy for Long Term Growth?",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-best-165618385.html"
            },
            {
                "headline": "Last week, Merck (NYSE:MRK) entered into a non-exclusive license and option agreement with Cyprumed GmbH, aiming to enhance its peptide offerings through innovative oral delivery technology. Despite this collaboration, Merck's share price remained essentially flat over the week. This lack of movement occurred amidst a broader market sell-off led by the technology sector, due to new U.S. restrictions on chip exports to China. While Merck's agreements showcased a strong focus on growth and...",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9186",
                "source": "Simply Wall St.",
                "ticker": "MRK",
                "title": "Merck (NYSE:MRK) Secures Global Rights To Cyprumed's Oral Peptide Delivery Technology",
                "url": "https://finance.yahoo.com/news/merck-nyse-mrk-secures-global-174624411.html"
            },
            {
                "headline": "We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co Inc. (NYSE:MRK) stands against other undervalued quality stocks to buy now. On February 24, Kayne Anderson Rudnick chief market strategist Julie Biel joined \u2018The Exchange\u2019 [\u2026]",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co Inc. (NYSE:MRK) the Most Undervalued Quality Stock to Buy Now?",
                "url": "https://finance.yahoo.com/news/merck-co-inc-nyse-mrk-135315697.html"
            },
            {
                "headline": "We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co Inc. (NYSE:MRK) stands against other undervalued quality stocks to buy now. On February 24, Kayne Anderson Rudnick chief market strategist Julie Biel joined \u2018The Exchange\u2019 [\u2026]",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co Inc. (NYSE:MRK) the Most Undervalued Quality Stock to Buy Now?",
                "url": "https://finance.yahoo.com/news/merck-co-inc-nyse-mrk-135315697.html"
            },
            {
                "headline": "Last week, Merck (NYSE:MRK) entered into a non-exclusive license and option agreement with Cyprumed GmbH, aiming to enhance its peptide offerings through innovative oral delivery technology. Despite this collaboration, Merck's share price remained essentially flat over the week. This lack of movement occurred amidst a broader market sell-off led by the technology sector, due to new U.S. restrictions on chip exports to China. While Merck's agreements showcased a strong focus on growth and...",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9186",
                "source": "Simply Wall St.",
                "ticker": "MRK",
                "title": "Merck (NYSE:MRK) Secures Global Rights To Cyprumed's Oral Peptide Delivery Technology",
                "url": "https://finance.yahoo.com/news/merck-nyse-mrk-secures-global-174624411.html"
            },
            {
                "headline": "We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big [\u2026]",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9274",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co., Inc. (MRK) the Best Pharma Stock to Buy for Long Term Growth?",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-best-165618385.html"
            }
        ],
        "avgScore": 0.6153333333333334,
        "pctChange": 0.020141262542077168
    },
    "4 15 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other high growth forever dividend stocks. Dividend stocks have trailed the broader market over the past two years, largely due to [\u2026]",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Merck & Co. Inc. (MRK): Among the High Growth Forever Dividend Stocks to Invest In",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-among-135935385.html"
            },
            {
                "headline": "We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other high growth forever dividend stocks. Dividend stocks have trailed the broader market over the past two years, largely due to [\u2026]",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Merck & Co. Inc. (MRK): Among the High Growth Forever Dividend Stocks to Invest In",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-among-135935385.html"
            }
        ],
        "avgScore": 0.6369,
        "pctChange": -0.024620491391796614
    },
    "4 14 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best medical stocks to buy according to billionaires. Why are Healthcare Stocks Under Pressure? Some experts view medical, healthcare, and [\u2026]",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.802",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co., Inc. (MRK) the Best Medical Stock to Buy According to Billionaires?",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-best-215759150.html"
            },
            {
                "headline": "Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5106",
                "source": "Zacks",
                "ticker": "MRK",
                "title": "ABBV vs. MRK: Which Drug Giant is a Better Buy Now?",
                "url": "https://finance.yahoo.com/news/abbv-vs-mrk-drug-giant-143700084.html"
            },
            {
                "headline": "We recently published a list of the 11 Cheap NYSE Stocks to Invest in According to Hedge Funds. In this article, we are going to take a look at where Merck & Co. (NYSE:MRK) stands against other cheap NYSE stocks. On March 26, Jack Caffrey of JPMorgan Asset Management provided an analysis of market trends [\u2026]",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3612",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co. (NYSE:MRK) a Cheap NYSE Stock to Invest in According to Hedge Funds?",
                "url": "https://finance.yahoo.com/news/merck-co-nyse-mrk-cheap-142910051.html"
            },
            {
                "headline": "We recently published a list of the 11 Cheap NYSE Stocks to Invest in According to Hedge Funds. In this article, we are going to take a look at where Merck & Co. (NYSE:MRK) stands against other cheap NYSE stocks. On March 26, Jack Caffrey of JPMorgan Asset Management provided an analysis of market trends [\u2026]",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3612",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co. (NYSE:MRK) a Cheap NYSE Stock to Invest in According to Hedge Funds?",
                "url": "https://finance.yahoo.com/news/merck-co-nyse-mrk-cheap-142910051.html"
            },
            {
                "headline": "Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5106",
                "source": "Zacks",
                "ticker": "MRK",
                "title": "ABBV vs. MRK: Which Drug Giant is a Better Buy Now?",
                "url": "https://finance.yahoo.com/news/abbv-vs-mrk-drug-giant-143700084.html"
            },
            {
                "headline": "We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best medical stocks to buy according to billionaires. Why are Healthcare Stocks Under Pressure? Some experts view medical, healthcare, and [\u2026]",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.802",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co., Inc. (MRK) the Best Medical Stock to Buy According to Billionaires?",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-best-215759150.html"
            }
        ],
        "avgScore": 0.5579333333333334,
        "pctChange": -0.009852201557872867
    },
    "4 11 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of Jim Cramer Recently Talked About These 9 Stocks. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE: MRK) stands against other stocks that Jim Cramer discussed recently. On Wednesday, Jim Cramer, the host of Mad Money, shared his thoughts on the [\u2026]",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2023",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Jim Cramer on Merck (MRK): Stay The Course\u2026 It\u2019s Been a Real Tough One",
                "url": "https://finance.yahoo.com/news/jim-cramer-merck-mrk-stay-163345390.html"
            },
            {
                "headline": "We recently published a list of Jim Cramer Recently Talked About These 9 Stocks. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE: MRK) stands against other stocks that Jim Cramer discussed recently. On Wednesday, Jim Cramer, the host of Mad Money, shared his thoughts on the [\u2026]",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2023",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Jim Cramer on Merck (MRK): Stay The Course\u2026 It\u2019s Been a Real Tough One",
                "url": "https://finance.yahoo.com/news/jim-cramer-merck-mrk-stay-163345390.html"
            }
        ],
        "avgScore": -0.2023,
        "pctChange": -0.0001263214977509281
    },
    "4 10 2025": {
        "importantArticles": [
            {
                "headline": "Merck (NYSE:MRK) recently experienced a significant corporate governance event when multiple shareholder proposals were announced, with the company recommending against them for the upcoming annual meeting. This development comes amid a general market downturn, underscored by the Dow and Nasdaq dropping 4% and 6%, respectively. Over the past week, Merck's share price has decreased by 5.42%, slightly exceeding the broader market's decline. The combination of these shareholder proposals and...",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "Simply Wall St.",
                "ticker": "MRK",
                "title": "Merck (NYSE:MRK) Faces Multiple Shareholder Proposals Ahead Of Annual Meeting",
                "url": "https://finance.yahoo.com/news/merck-nyse-mrk-faces-multiple-172317255.html"
            },
            {
                "headline": "We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Charly AI. In this article, we will summarize the bulls\u2019 thesis on MRK. Merck & Co., Inc. (MRK)\u2019s share was trading at $81.91 as of April 9th. MRK\u2019s trailing and forward P/E were 12.15 and 9.10 respectively according to Yahoo Finance. Merck [\u2026]",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Merck & Co., Inc. (MRK): A Bull Case Theory",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-bull-125550249.html"
            },
            {
                "headline": "Pharma stocks tumbled Thursday after the Trump administration said the delay for reciprocal tariffs doesn't apply to sector-specific tariffs.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "Investor's Business Daily",
                "ticker": "MRK",
                "title": "S&P, Dow Jones Pharma Names Rattled \u2014 Again \u2014 On Trump's Tariffs Whiplash",
                "url": "https://finance.yahoo.com/m/5788e167-ba2e-3f2d-8e9e-4bfb72e0e2c1/s-p-dow-jones-pharma-names.html"
            },
            {
                "headline": "Pharma stocks tumbled Thursday after the Trump administration said the delay for reciprocal tariffs doesn't apply to sector-specific tariffs.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "Investor's Business Daily",
                "ticker": "MRK",
                "title": "S&P, Dow Jones Pharma Names Rattled \u2014 Again \u2014 On Trump's Tariffs Whiplash",
                "url": "https://finance.yahoo.com/m/5788e167-ba2e-3f2d-8e9e-4bfb72e0e2c1/s-p-dow-jones-pharma-names.html"
            },
            {
                "headline": "We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Charly AI. In this article, we will summarize the bulls\u2019 thesis on MRK. Merck & Co., Inc. (MRK)\u2019s share was trading at $81.91 as of April 9th. MRK\u2019s trailing and forward P/E were 12.15 and 9.10 respectively according to Yahoo Finance. Merck [\u2026]",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Merck & Co., Inc. (MRK): A Bull Case Theory",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-bull-125550249.html"
            },
            {
                "headline": "Merck (NYSE:MRK) recently experienced a significant corporate governance event when multiple shareholder proposals were announced, with the company recommending against them for the upcoming annual meeting. This development comes amid a general market downturn, underscored by the Dow and Nasdaq dropping 4% and 6%, respectively. Over the past week, Merck's share price has decreased by 5.42%, slightly exceeding the broader market's decline. The combination of these shareholder proposals and...",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "Simply Wall St.",
                "ticker": "MRK",
                "title": "Merck (NYSE:MRK) Faces Multiple Shareholder Proposals Ahead Of Annual Meeting",
                "url": "https://finance.yahoo.com/news/merck-nyse-mrk-faces-multiple-172317255.html"
            }
        ],
        "avgScore": 0.29963333333333325,
        "pctChange": 0.021018661370394646
    },
    "4 9 2025": {
        "importantArticles": [
            {
                "headline": "Catalysts host Madison Mills and Trader Talk podcast host Kenny Polcari take a look at some of the day's top trending stocks. Apple (AAPL) is in focus after Microsoft (MSFT) replaced Apple as the most valuable company. Alibaba (BABA) reverses earlier gains after US tariffs went into effect. Drugmaker stocks, including Pfizer (PFE), Merck (MRK), and Eli Lilly (LLY), are falling after President Trump announced that pharmaceutical tariffs may be on the way. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7178",
                "source": "Yahoo Finance Video",
                "ticker": "MRK",
                "title": "Apple, Alibaba, drugmaker stocks: Trending Tickers",
                "url": "https://finance.yahoo.com/video/apple-alibaba-drugmaker-stocks-trending-144322260.html"
            },
            {
                "headline": "We recently published a list of 10 Defensive Stocks Billionaire Ken Fisher is Betting On. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other defensive stocks billionaire Ken Fisher is betting on. Ken Fisher, an American billionaire investor, author, and financial analyst, founded and runs Fisher [\u2026]",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.0516",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Merck & Co., Inc. (MRK): Among Defensive Stocks Billionaire Ken Fisher is Betting On",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-among-221507847.html"
            },
            {
                "headline": "Pharma names whipsawed Wednesday after Trump said he would enact \"major\" tariffs on drug imports and then backed off his tariffs \u2014 for now.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0258",
                "source": "Investor's Business Daily",
                "ticker": "MRK",
                "title": "Dow Jones, S&P 500 Pharma Names Recover After Trump Backs Off His Tariffs Plan",
                "url": "https://finance.yahoo.com/m/be7d1b24-7c1e-38ff-91b2-281ea7807568/dow-jones-s-p-500-pharma.html"
            },
            {
                "headline": "Drugmaker stocks, including Eli Lilly (LLY), Johnson & Johnson (JNJ), Merck (MRK), and Pfizer (PFE), are under pressure on Wednesday after President Trump announced that he may impose tariffs on pharmaceutical imports. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Morning Brief to break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Yahoo Finance Video",
                "ticker": "MRK",
                "title": "Trump says pharmaceutical tariffs may be coming: What to know",
                "url": "https://finance.yahoo.com/video/trump-says-pharmaceutical-tariffs-may-141157823.html"
            },
            {
                "headline": "Trump tariff news: President Trump's latest tariffs took effect Wednesday while China stepped up retaliation. Treasury yields are worrisome. Walmart and Delta Air pulled some guidance, citing tariff uncertainty.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5106",
                "source": "Investor's Business Daily",
                "ticker": "MRK",
                "title": "Trump Tariff News: New Tariffs Begin, China Retaliates; Treasury Yields Spike While Delta, Walmart Pull Guidance",
                "url": "https://finance.yahoo.com/m/a3b4073e-cf6b-3c9f-8915-5acaa3968de0/trump-tariff-news-new.html"
            },
            {
                "headline": "Pharma names whipsawed Wednesday after Trump said he would enact \"major\" tariffs on drug imports and then backed off his tariffs \u2014 for now.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0258",
                "source": "Investor's Business Daily",
                "ticker": "MRK",
                "title": "Dow Jones, S&P 500 Pharma Names Recover After Trump Backs Off His Tariffs Plan",
                "url": "https://finance.yahoo.com/m/be7d1b24-7c1e-38ff-91b2-281ea7807568/dow-jones-s-p-500-pharma.html"
            }
        ],
        "avgScore": -0.04842,
        "pctChange": -0.053229159021127584
    },
    "4 8 2025": {
        "importantArticles": [
            {
                "headline": "Quarterly earnings results are a good time to check in on a company\u2019s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst performers in the branded pharmaceuticals industry.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7003",
                "source": "StockStory",
                "ticker": "MRK",
                "title": "Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment",
                "url": "https://finance.yahoo.com/news/q4-earnings-roundup-organon-nyse-090718154.html"
            },
            {
                "headline": "Walgreens (WBA) stock is rising after the company reported better-than-expected second quarter earnings while preparing for privatization. Yahoo Finance Senior Health Reporter Anjalee Khemlani highlights the company's cost management strategy, CVS's (CVS) leadership changes amid similar challenges in the retail drug sector, and moves by US drug makers, like Merck (MRK), Johnson & Johnson (JNJ), and Eli Lilly (LLY), as they prepare for incoming tariffs. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4215",
                "source": "Yahoo Finance Video",
                "ticker": "MRK",
                "title": "Walgreens, CVS, & US drugmakers make big moves: What to know",
                "url": "https://finance.yahoo.com/video/walgreens-cvs-us-drugmakers-big-140318681.html"
            },
            {
                "headline": "Walgreens (WBA) stock is rising after the company reported better-than-expected second quarter earnings while preparing for privatization. Yahoo Finance Senior Health Reporter Anjalee Khemlani highlights the company's cost management strategy, CVS's (CVS) leadership changes amid similar challenges in the retail drug sector, and moves by US drug makers, like Merck (MRK), Johnson & Johnson (JNJ), and Eli Lilly (LLY), as they prepare for incoming tariffs. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4215",
                "source": "Yahoo Finance Video",
                "ticker": "MRK",
                "title": "Walgreens, CVS, & US drugmakers make big moves: What to know",
                "url": "https://finance.yahoo.com/video/walgreens-cvs-us-drugmakers-big-140318681.html"
            },
            {
                "headline": "Quarterly earnings results are a good time to check in on a company\u2019s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst performers in the branded pharmaceuticals industry.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7003",
                "source": "StockStory",
                "ticker": "MRK",
                "title": "Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment",
                "url": "https://finance.yahoo.com/news/q4-earnings-roundup-organon-nyse-090718154.html"
            }
        ],
        "avgScore": 0.5609,
        "pctChange": 0.03749217008593047
    },
    "4 7 2025": {
        "importantArticles": [
            {
                "headline": "The past six months haven\u2019t been great for Merck. It just made a new 52-week low of $79.69, and shareholders have lost 26.6% of their capital. This was partly due to its softer quarterly results and might have investors contemplating their next move.",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1779",
                "source": "StockStory",
                "ticker": "MRK",
                "title": "2 Reasons to Like MRK (and 1 Not So Much)",
                "url": "https://finance.yahoo.com/news/2-reasons-mrk-1-not-091045372.html"
            },
            {
                "headline": "The past six months haven\u2019t been great for Merck. It just made a new 52-week low of $79.69, and shareholders have lost 26.6% of their capital. This was partly due to its softer quarterly results and might have investors contemplating their next move.",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1779",
                "source": "StockStory",
                "ticker": "MRK",
                "title": "2 Reasons to Like MRK (and 1 Not So Much)",
                "url": "https://finance.yahoo.com/news/2-reasons-mrk-1-not-091045372.html"
            }
        ],
        "avgScore": 0.1779,
        "pctChange": -0.02746986140121283
    },
    "4 3 2025": {
        "importantArticles": [
            {
                "headline": "Big pharmaceutical stocks mostly rose after President Trump\u2019s executive order exempted medicines from new tariffs. Merck, Bristol-Myers Squibb, and Johnson & Johnson were among the top performers in the S&P 500, with the sector also benefiting from its status as a defensive play.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5106",
                "source": "The Wall Street Journal",
                "ticker": "MRK",
                "title": "Pharma Stocks Aren't in the Clear, Despite Tariff Exemption\u2014Heard on the Street",
                "url": "https://finance.yahoo.com/m/4d202ae2-292d-33fc-b5df-f9468db0055c/pharma-stocks-aren-t-in-the.html"
            },
            {
                "headline": "Big pharmaceutical stocks mostly rose after President Trump\u2019s executive order exempted medicines from new tariffs. Merck, Bristol-Myers Squibb, and Johnson & Johnson were among the top performers in the S&P 500, with the sector also benefiting from its status as a defensive play.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5106",
                "source": "The Wall Street Journal",
                "ticker": "MRK",
                "title": "Pharma Stocks Aren't in the Clear, Despite Tariff Exemption\u2014Heard on the Street",
                "url": "https://finance.yahoo.com/m/4d202ae2-292d-33fc-b5df-f9468db0055c/pharma-stocks-aren-t-in-the.html"
            }
        ],
        "avgScore": 0.5106,
        "pctChange": -0.05695101520668427
    },
    "4 2 2025": {
        "importantArticles": [
            {
                "headline": "As the U.S. stock market experiences volatility amid anticipation of new tariff announcements from President Trump, investors are keenly observing how these trade measures might impact economic growth and inflation. In such an uncertain environment, dividend stocks can offer a measure of stability and income through regular payouts, making them attractive options for those seeking to balance risk with potential returns.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "Simply Wall St.",
                "ticker": "MRK",
                "title": "3 Dividend Stocks To Consider With Yields Up To 4.2%",
                "url": "https://finance.yahoo.com/news/3-dividend-stocks-consider-yields-170138184.html"
            },
            {
                "headline": "The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.25",
                "source": "Zacks",
                "ticker": "MRK",
                "title": "Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?",
                "url": "https://finance.yahoo.com/news/wall-street-analysts-think-merck-133010906.html"
            },
            {
                "headline": "Amazon.com, Oracle and Merck are part of the Zacks top Analyst Blog.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2023",
                "source": "Zacks",
                "ticker": "MRK",
                "title": "The Zacks Analyst Blog Highlights Amazon.com, Oracle and Merck",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-amazon-131400616.html"
            },
            {
                "headline": "Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Oracle Corp. (ORCL) and Merck & Co., Inc. (MRK).",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "MRK",
                "title": "Top Analyst Reports for Amazon, Oracle & Merck",
                "url": "https://finance.yahoo.com/news/top-analyst-reports-amazon-oracle-205900596.html"
            },
            {
                "headline": "Amazon.com, Oracle and Merck are part of the Zacks top Analyst Blog.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2023",
                "source": "Zacks",
                "ticker": "MRK",
                "title": "The Zacks Analyst Blog Highlights Amazon.com, Oracle and Merck",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-amazon-131400616.html"
            },
            {
                "headline": "The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.25",
                "source": "Zacks",
                "ticker": "MRK",
                "title": "Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?",
                "url": "https://finance.yahoo.com/news/wall-street-analysts-think-merck-133010906.html"
            }
        ],
        "avgScore": 0.252425,
        "pctChange": -0.002424931734097095
    },
    "4 1 2025": {
        "importantArticles": [
            {
                "headline": "RAHWAY, N.J., April 01, 2025--Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Business Wire",
                "ticker": "MRK",
                "title": "Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24",
                "url": "https://finance.yahoo.com/news/merck-hold-first-quarter-2025-104500687.html"
            },
            {
                "headline": "AstraZeneca said Monday its experimental pill lowered \"bad\" LDL cholesterol by 51%. But AstraZeneca stock fell in line with pharma stocks.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0644",
                "source": "Investor's Business Daily",
                "ticker": "MRK",
                "title": "Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?",
                "url": "https://finance.yahoo.com/m/88800b5c-ff5c-3c4f-bae4-af0c19fd8b46/does-astrazeneca-have-one.html"
            },
            {
                "headline": "AstraZeneca said Monday its experimental pill lowered \"bad\" LDL cholesterol by 51%. But AstraZeneca stock fell in line with pharma stocks.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0644",
                "source": "Investor's Business Daily",
                "ticker": "MRK",
                "title": "Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?",
                "url": "https://finance.yahoo.com/m/88800b5c-ff5c-3c4f-bae4-af0c19fd8b46/does-astrazeneca-have-one.html"
            },
            {
                "headline": "RAHWAY, N.J., April 01, 2025--Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Business Wire",
                "ticker": "MRK",
                "title": "Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24",
                "url": "https://finance.yahoo.com/news/merck-hold-first-quarter-2025-104500687.html"
            }
        ],
        "avgScore": -0.0322,
        "pctChange": -0.005968827548979144
    },
    "3 31 2025": {
        "importantArticles": [
            {
                "headline": "Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining by 3.3%. This decrease in share price coincides with broader market trends, including steep losses in major indices due to looming tariffs and economic uncertainty, which have also impacted Merck's peer companies. Despite the positive drug trial outcomes and regulatory progress with CAPVAXIVE and...",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.6041",
                "source": "Simply Wall St.",
                "ticker": "MRK",
                "title": "Merck (NYSE:MRK) Reports Strong Phase 3 Results For WINREVAIR In PAH Treatment",
                "url": "https://finance.yahoo.com/news/merck-nyse-mrk-reports-strong-173141485.html"
            },
            {
                "headline": "RAHWAY, N.J., March 31, 2025--WINREVAIR reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for PAH by 76% vs. placebo in ZENITH trial.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7184",
                "source": "Business Wire",
                "ticker": "MRK",
                "title": "WINREVAIR\u2122 (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial",
                "url": "https://finance.yahoo.com/news/winrevair-sotatercept-csrk-reduced-risk-140000714.html"
            },
            {
                "headline": "RAHWAY, N.J., March 31, 2025--WINREVAIR reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for PAH by 76% vs. placebo in ZENITH trial.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7184",
                "source": "Business Wire",
                "ticker": "MRK",
                "title": "WINREVAIR\u2122 (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial",
                "url": "https://finance.yahoo.com/news/winrevair-sotatercept-csrk-reduced-risk-140000714.html"
            },
            {
                "headline": "Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining by 3.3%. This decrease in share price coincides with broader market trends, including steep losses in major indices due to looming tariffs and economic uncertainty, which have also impacted Merck's peer companies. Despite the positive drug trial outcomes and regulatory progress with CAPVAXIVE and...",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.6041",
                "source": "Simply Wall St.",
                "ticker": "MRK",
                "title": "Merck (NYSE:MRK) Reports Strong Phase 3 Results For WINREVAIR In PAH Treatment",
                "url": "https://finance.yahoo.com/news/merck-nyse-mrk-reports-strong-173141485.html"
            }
        ],
        "avgScore": -0.66125,
        "pctChange": -0.02941175720608451
    },
    "3 28 2025": {
        "importantArticles": [
            {
                "headline": "The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at least as effective as the IV version.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4767",
                "source": "Zacks",
                "ticker": "MRK",
                "title": "FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda",
                "url": "https://finance.yahoo.com/news/fda-accepts-mercks-filing-subcutaneous-152000184.html"
            },
            {
                "headline": "The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4767",
                "source": "Investor's Business Daily",
                "ticker": "MRK",
                "title": "Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?",
                "url": "https://finance.yahoo.com/m/7fa62fa5-4885-32e4-a151-464172a9773f/merck-s-biggest-moneymaker.html"
            },
            {
                "headline": "We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other low volatility stocks to buy according to billionaire Ken Fisher. Billionaire Ken Fisher, a prominent money manager, renowned [\u2026]",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2263",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co. (MRK) the Low Volatility Stock to Buy According to Billionaire Ken Fisher?",
                "url": "https://finance.yahoo.com/news/merck-co-mrk-low-volatility-213637264.html"
            },
            {
                "headline": "Merck & Co. (MRK) releases positive phase three data for its injectable-form cancer drug Keytruda. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Domination to break down the company's new data. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.296",
                "source": "Yahoo Finance Video",
                "ticker": "MRK",
                "title": "Merck releases positive data for blockbuster cancer drug",
                "url": "https://finance.yahoo.com/video/merck-releases-positive-data-blockbuster-201400957.html"
            },
            {
                "headline": "We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other low volatility stocks to buy according to billionaire Ken Fisher. Billionaire Ken Fisher, a prominent money manager, renowned [\u2026]",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2263",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co. (MRK) the Low Volatility Stock to Buy According to Billionaire Ken Fisher?",
                "url": "https://finance.yahoo.com/news/merck-co-mrk-low-volatility-213637264.html"
            },
            {
                "headline": "The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4767",
                "source": "Investor's Business Daily",
                "ticker": "MRK",
                "title": "Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?",
                "url": "https://finance.yahoo.com/m/7fa62fa5-4885-32e4-a151-464172a9773f/merck-s-biggest-moneymaker.html"
            }
        ],
        "avgScore": 0.10777500000000002,
        "pctChange": 0.0059396924729095794
    },
    "3 27 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 12 Best Consistent Dividend Stocks to Buy. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best consistent dividend stocks to buy. Over the past two years, persistently high inflation has led to increased borrowing costs, creating a [\u2026]",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9136",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co., Inc. (MRK) the Best Consistent Dividend Stock to Buy?",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-best-220946172.html"
            },
            {
                "headline": "Merck has filed for approval for a new drug that could buoy the bottom line from headwinds in recent months.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4767",
                "source": "Yahoo Finance",
                "ticker": "MRK",
                "title": "Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form",
                "url": "https://finance.yahoo.com/news/positive-phase-iii-data-gives-merck-potential-boost-for-blockbuster-keytruda-in-injection-form-150009481.html"
            },
            {
                "headline": "RAHWAY, N.J., March 27, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administration of pembrolizumab, together with berahyaluronidase alfa (MK-3475A; from now on referred to as \"subcutaneous pembrolizumab\"). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. These results are being presented today a",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4215",
                "source": "Business Wire",
                "ticker": "MRK",
                "title": "Merck\u2019s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA\u00ae (pembrolizumab) in Pivotal 3475A-D77 Trial",
                "url": "https://finance.yahoo.com/news/merck-investigational-subcutaneous-pembrolizumab-berahyaluronidase-150100421.html"
            },
            {
                "headline": "We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, expressed his frustration on March 19 about how investors [\u2026]",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5719",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Here is Why Jim Cramer Is Bullish About Merck (MRK)",
                "url": "https://finance.yahoo.com/news/why-jim-cramer-bullish-merck-014113098.html"
            },
            {
                "headline": "RAHWAY, N.J., March 27, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administration of pembrolizumab, together with berahyaluronidase alfa (MK-3475A; from now on referred to as \"subcutaneous pembrolizumab\"). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. These results are being presented today a",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4215",
                "source": "Business Wire",
                "ticker": "MRK",
                "title": "Merck\u2019s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA\u00ae (pembrolizumab) in Pivotal 3475A-D77 Trial",
                "url": "https://finance.yahoo.com/news/merck-investigational-subcutaneous-pembrolizumab-berahyaluronidase-150100421.html"
            },
            {
                "headline": "Merck has filed for approval for a new drug that could buoy the bottom line from headwinds in recent months.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4767",
                "source": "Yahoo Finance",
                "ticker": "MRK",
                "title": "Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form",
                "url": "https://finance.yahoo.com/news/positive-phase-iii-data-gives-merck-potential-boost-for-blockbuster-keytruda-in-injection-form-150009481.html"
            }
        ],
        "avgScore": 0.309975,
        "pctChange": 0.018607362000058005
    },
    "3 26 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other best defensive stocks amid market volatility. With ongoing inflation, economic uncertainty, and global tensions, more investors are looking for ways to protect [\u2026]",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7964",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Is Merck & Co. Inc. (MRK) The Best Defensive Stock Amid Market Volatility?",
                "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-best-214851022.html"
            },
            {
                "headline": "Big Pharma taps Chinese innovation again--this time for a potential blockbuster heart treatment targeting 1.4B people.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7579",
                "source": "GuruFocus.com",
                "ticker": "MRK",
                "title": "Merck Bets $2B on China's Hengrui for Next Big Heart Drug",
                "url": "https://finance.yahoo.com/news/merck-bets-2b-chinas-hengrui-190053022.html"
            },
            {
                "headline": "Merck (NYSE:MRK) has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE\u00ae, boosting its portfolio in the vaccines market. Despite this positive development, the company's share price encountered a 1.82% decline over the last month, a period marked by substantial turmoil across global markets. Influenced by concerns related to potential U.S. tariffs and the broader selloff in the technology sector, many investors were...",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5259",
                "source": "Simply Wall St.",
                "ticker": "MRK",
                "title": "Merck (NYSE:MRK) Gains EC Approval For CAPVAXIVE\u00ae Amid Recent 7% Share Price Dip",
                "url": "https://finance.yahoo.com/news/merck-nyse-mrk-gains-ec-173210476.html"
            },
            {
                "headline": "We recently published a list of Pulse of The Market: Tuesday\u2019s 10 Worst Performers. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other Tuesday\u2019s worst performers. Wall Street finished Tuesday\u2019s trading in a lackluster fashion, with all major indices ending in the green territory, [\u2026]",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.8481",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Why Merck & Co. Inc. (MRK) Performed Worst On Tuesday?",
                "url": "https://finance.yahoo.com/news/why-merck-co-inc-mrk-091950707.html"
            },
            {
                "headline": "We recently published a list of Jim Cramer Recently Put These 10 Stocks Under Spotlight. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks that Jim Cramer discussed recently. On Monday, Jim Cramer, host of Mad Money, shared his thoughts on how the [\u2026]",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2023",
                "source": "Insider Monkey",
                "ticker": "MRK",
                "title": "Jim Cramer on Merck (MRK): \u201cI Like It at This Level \u2013 But I Like Bristol-Myers Even More!\u201d",
                "url": "https://finance.yahoo.com/news/jim-cramer-merck-mrk-level-174513723.html"
            },
            {
                "headline": "RAHWAY, N.J., March 26, 2025--European Commission (EC) Approves Merck\u2019s CAPVAXIVE\u00ae for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4019",
                "source": "Business Wire",
                "ticker": "MRK",
                "title": "European Commission (EC) Approves Merck\u2019s CAPVAXIVE\u00ae (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults",
                "url": "https://finance.yahoo.com/news/european-commission-ec-approves-merck-104500234.html"
            }
        ],
        "avgScore": 0.23861666666666662,
        "pctChange": -0.005788243476309219
    },
    "coef": 0.11729323308270674,
    "avgCoef": 0.013112524913912434,
    "similar": {
        "GRAB": 0.3082706766917293,
        "BBD": 0.2776524488029912,
        "ITUB": 0.27669172932330827,
        "PONY": 0.26766917293233083
    }
}